The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A randomized phase II/III trial of a tumor vascular disrupting agent fosbretabulin tromethamine (CA4P) with carboplatin (C) and paclitaxel (P) in anaplastic thyroid cancer (ATC): Final survival analysis for the FACT trial.
J. A. Sosa
No relevant relationships to disclose
R. Elisei
No relevant relationships to disclose
B. Jarzab
Research Funding - Oxigene
C. S. Bal
No relevant relationships to disclose
H. Koussis
No relevant relationships to disclose
A. W. Gramza
No relevant relationships to disclose
R. Ben-Yosef
No relevant relationships to disclose
B. J. Gitlitz
No relevant relationships to disclose
B. Haugen
No relevant relationships to disclose
S. M. Karandikar
No relevant relationships to disclose
F. R. Khuri
Consultant or Advisory Role - Pfizer
Honoraria - Pfizer
Research Funding - Novartis
L. F. Licitra
No relevant relationships to disclose
S. C. Remick
Honoraria - Oxigene
Research Funding - Oxigene
S. Marur
Research Funding - Oxigene
C. Lu
No relevant relationships to disclose
F. G. Ondrey
No relevant relationships to disclose
S. Lu
Employment or Leadership Position - Oxigene
J. Balkissoon
Employment or Leadership Position - Oxigene
Stock Ownership - Oxigene